Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
02:00am, Friday, 28'th Mar 2025
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adu
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
06:47pm, Tuesday, 25'th Mar 2025
As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they trad
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
04:05pm, Tuesday, 25'th Mar 2025
TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Inves
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
09:40am, Friday, 14'th Mar 2025
Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led to i
3 Stocks With Ironclad Balance Sheets for Long-Term Stability
07:23am, Thursday, 13'th Mar 2025
Although sometimes overshadowed by the all-important income statement, the balance sheet can offer essential insights into a company's financial health. It revolves around the balance between a compan
$250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition TARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 /PRNewswire/ -- Regeneron Pharma
$250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition $250,000 top award goes to Matteo Paz in America's longest running and most disti
Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners 2025 Global Healthcare Conference Call Transcript
10:25am, Tuesday, 11'th Mar 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET Company Participants Ryan Crowe - SVP, IR & Strategic Analysis Chris Fe
NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regen
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
04:45pm, Monday, 10'th Mar 2025
LOS ANGELES--(BUSINESS WIRE)--REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Investors can contact the law firm at no cost to learn more about recovering their losses
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
04:15pm, Monday, 10'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal
